The acquisition of successful small- to medium-sized pharmaceutical companies by a larger market player and the additional funds and resources this provides can really propel research forward. Equally, it is one of many strategies that bigger companies use to reduce some of the financial risk associated with carrying out their own in-house research.
Whatever the motivation, it is important that the potential drugs and commercial processes have adequate protection. Without sufficient and demonstrable market exclusivity, interest in an M&A discussion may be hard to come by. So if you are a small- to mid-sized pharmaceutical . . .
This content is restricted to subscribers. To view this content please register an account.
If you are already a subscriber, please login below.